The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.
- Mechanism
- Curator reviewed
A distinguishing feature of the BILN 2061 inhibitor series is the presence of C-terminal carboxylic acid functionality. This provides exquisite selectivity with respect to other proteases, a property not easily attained with more conventional classes of covalent, reversible serine protease inhibitors. BILN 2061 blocks NS3 protease-dependent polyprotein processing in HCV replicon-containing cells. It is orally bioavailable in various animal species.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
- Formula / weight
- C40H50N6O8S · 774.925 g/mol (avg)
- Code names
- BILN 2061 · BILN 2061 ZW
Resolves to
PJZPDFUUXKKDNB-KNINVFKUSA-NSMILESCOC1=CC2=C(C=C1)C(O[C@H]1CN3C(=O)[C@H](CCCCC\C=C/[C@]4([H])C[C@@]4(C(O)=O)NC(=O)[C@]3([H])C1)NC(=O)OC1CCCC1)=CC(=N2)C1=CSC(NC(C)C)=N1What you can answer from here — as of September 23, 2026
Which drugs share a target with Ciluprevir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account